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Abstract
Naltrexone is not recommended during pregnancy. However, sustained-release naltrexone implant use in humans has
resulted in cases of inadvertent foetal exposure. Here, we used clinically relevant dosing to examine the effects of maternally
administered sustained-release naltrexone on the rat brain by examining offspring at birth and in adulthood. Maternal
treatment (naltrexone or placebo implant) started before conception and ceased during gestation, birth or weaning.
Morphometry was assessed in offspring at birth and adulthood. Adult offspring were evaluated for differences in locomotor
behaviour (basal and morphine-induced, 10 mg/kg, s.c.) and opioid neurochemistry, propensity to self-administer morphine
and cue-induced drug-seeking after abstinence. Blood analysis confirmed offspring exposure to naltrexone during
gestation, birth and weaning. Naltrexone exposure increased litter size and reduced offspring birth-weight but did not alter
brain morphometry. Compared to placebo, basal motor activity of naltrexone-exposed adult offspring was lower, yet they
showed enhanced development of psychomotor sensitization to morphine. Developmental naltrexone exposure was
associated with resistance to morphine-induced down-regulation of striatal preproenkephalin mRNA expression in
adulthood. Adult offspring also exhibited greater operant responding for morphine and, in addition, cue-induced drug-
seeking was enhanced. Collectively, these data show pronounced effects of developmental naltrexone exposure, some of
which persist into adulthood, highlighting the need for follow up of humans that were exposed to naltrexone in utero.
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Introduction
Naltrexone is a non-selective opioid receptor antagonist [1],
used clinically for persons wanting to abstain from opiates [2]
and/or alcohol [3,4]. However, naltrexone is not recommended
during pregnancy [5]. Unfortunately, some pregnant opioid-
dependent women have received oral naltrexone [6]. Moreover,
with the advent of sustained-release naltrexone preparations and
their emerging clinical use, inadvertent foetal naltrexone exposure,
particularly around conception, is a genuine possibility [7]. To
date, 52 women have become pregnant while being treated with
an Australian naltrexone implant (GKH, personal communica-
tion).
Limited data from humans treated with oral or sustained-release
naltrexone suggest no major adverse neonatal outcomes with
respect to birth-weights, APGAR scores and head circumferences
[6,8,9] but long-term follow-up is lacking. However, animal
studies, primarily in rat, show adverse neonatal outcomes, but
involved daily subcutaneous injections given directly to postnatal
offspring rather than clinically relevant maternal (i.e. indirect) and
sustained naltrexone exposure. The primary objective of this study
was to use a rat model of maternal administration involving
sustained-release of naltrexone throughout gestation and lactation
at a clinically-relevant plasma concentration of ,2–10 ng/ml
[7,10] and to determine outcomes in neonates and adult offspring.
Previous studies show that rat neonates directly receiving low-
dose naltrexone (1 mg/kg/day) are growth retarded [11,12]
whereas those exposed to high doses (50 mg/kg/day) have
increased birth-weights [13,14]. We therefore assessed the
morphometric impact of our sustained-release maternal naltrex-
one exposure regime hypothesizing that low-dose sustained-release
naltrexone exposure would result in reduced birth-weights.
Furthermore, it has been shown that perinatal exposure to
naltrexone (1–50 mg/kg/day) can alter aspects of adult offspring
behaviour pertaining to emotionality, exploratory drive and
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analgesic response to morphine [15,16,17,18]. However, changes
to locomotor activity are reported not to occur, and to date, no
studies are known to have assessed morphine-induced psychomo-
tor sensitization, an indicator of drug-induced plasticity pertinent
to aspects of addiction [19,20]. Moreover, morphine self-
administration experiments have not yet been undertaken in
naltrexone-exposed offspring. Nonetheless, prenatal exposure to
naltrexone can reduce sensitivity to morphine as indicated by
decreased open-field locomotion [18]. We therefore assessed
morphine-induced sensitization and intravenous morphine self-
administration in maternally exposed adult offspring. Given that
prenatal naltrexone exposure reduces the density of m-opioid
receptors in offspring with reduced morphine-induced locomotor
activity [18], we analysed opioid neurochemistry, namely m-opioid
receptor [21,22] as well as mRNA for preproenkephalin (PPE) and
preprodynorphin (PPD) [23].
Materials and Methods
Animals
Experiments adhered to the Prevention of Cruelty to Animals
Act, 1986 and the Australian National Health and Medical
Research Council Code of Practice for the Care and Use of
Animals for Experimental Purposes in Australia. There were 3
cohorts. Procedures for cohort 1 were approved by the Animal
Ethics Committee of the University of Western Australia, Perth,
Australia (Approval Number: RA 3 100 423) and the Florey
Neuroscience Institutes, Melbourne, Australia (Approval Numbers
05-061). Procedures for cohorts 2 and 3 were approved by the
Animal Ethics Committee of the University of Western Australia,
Perth, Australia (Approval Number: RA 3 100 618) and the Florey
Neuroscience Institutes, Melbourne, Australia (Approval Number:
08-001).
Three cohorts (Figure 1) of Sprague-Dawley rats (Animal
Resource Centre, Murdoch University, Australia) were housed in
pairs or threes (23uC; 12-h light/dark cycle) with food/water
available ad libitum. All females were nulliparous and 9–11 weeks of
age upon arrival. In cohort 1, there were 16 dams (180–270 g), in
cohort 2 there were 12/treatment group (197–315 g) and in
cohort 3 there were 6/treatment group (240–290 g). Ten males
(330–460 g) were used for husbandry.
Drugs
Morphine hydrochloride: Glaxo, Australia, in sterile 0.9%
saline. Ketamine: Parnell Laboratories, Australia; meloxicam:
Boeringher Ingleheim, Germany; neomycin sulfate: Delta Veter-
inary Laboratories, Australia; and carprofen: Norbrook Labora-
tories, Australia. Heparinised saline was diluted at 90 IU/ml.
Custom-sized naltrexone implants comprised the same formu-
lation as for humans (naltrexone-loaded poly[trans-3,6-dimethyl-
1,4-dioxyane-2,5-dione] (DL-lactide) microspheres, average mo-
lecular weight 700,000 Mv, inherent viscosity 0.5 dl/g, specific
Figure 1. Timelines and overall study design. Timelines and overall study design is shown for all 3 cohorts, including main procedures (i.e.
events) and offspring ages (A and B), experimental outcome measures (A), and sampling of blood/amniotic fluid (B). Each cohort can be identified by
their respective arrows (cohort 1, black-dashed; cohort 2, black-filled; cohort 3, gray-filled), which provide a guide for the procedures that were
undertaken and the approximate end-point. * maternal implant excision and histopathology data published elsewhere [45]. More detailed timelines
for the behavioural sensitization and operant self-administration experiments are presented in Figures 2 and 3, respectively.
doi:10.1371/journal.pone.0052812.g001
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rotation of –2u to +2u) compressed into a tablet (total weight:
50 mg; 25 mg naltrexone, 25 mg poly[DL-lactide]; 5 mm diam-
eter 6 2 mm height) surrounded by a single coat of poly(DL-
lactide) [24]. Placebo implants had the same dimensions and
contained 50 mg of poly(DL-lactide) microspheres. All implants
were sterilised using irradiation (range 25–40 KGy). Previous
in vitro (data not shown) and in vivo experiments [24] demonstrate
that the custom-sized implant used here has similar release rates
(0.4–0.8%/day) and plasma levels (2–10 ng/ml) to that measured
during their use in humans [10,25].
General Procedures
Three cohorts were used in the current study to evaluate the
extent of naltrexone exposure in offspring and dams during
pregnancy (cohort 1) and before/after pregnancy (cohorts 2 and
3), evaluate gross anatomical outcomes in offspring at birth and
adulthood and changes in neurochemistry in adulthood (cohort 2),
as well as evaluate behavioural outcomes in adult offspring
(cohorts 2 and 3). An overview of the experimental design and
timing of events/outcome measures for cohorts 1, 2 and 3 is
presented in Figure 1A.
Surgery. Dams had a single naltrexone or placebo implant
inserted subcutaneously under general anaesthesia (2–3% isoflur-
ane). Carprofen (5 mg/kg, s.c.) and neomycin (50 mg/kg, s.c.)
were injected post-operatively. Dams in cohort 1 were implanted
with naltrexone and those in cohorts 2 and 3 with naltrexone or
placebo implants.
Blood sampling and analysis. Blood was collected into
lithium-heparinised tubes and frozen at 280uC. For cohort 1,
maternal blood was obtained from a lateral tail vein [26] and
samples from foetal/neonatal rats by jugular incision, pooling
from each litter. Amniotic fluid was also pooled. All other maternal
and offspring samples (cohorts 1, 2 and 3) were obtained by
incising the atrium after terminal anaesthesia. The concentrations
of free naltrexone and 6,b-naltrexol in blood and amniotic fluid
samples were determined (Perth Chemistry Centre, Australia) by
liquid-chromatography/mass-spectrometry (LCMS) [27]. Report-
ing limits were 0.2 ng/ml for naltrexone and 0.1 ng/ml for 6,b-
naltrexol.
Timed mating. Initiation of timed mating took place 12 days
after surgical insertion of implants. Timed-matings were under-
taken by placement of nulliparous rat dams with 2–3 males
overnight; mating was confirmed the following morning by the
presence of spermatozoa in vaginal smears. In most cases,
conception occurred within 3–5 days of initial presentation to
males.
Figure 2. Timeline and paradigm for behavioural sensitization experiment: offspring from cohort 2. Treatments are shown (habituation,
daily injection with morphine [10 mg/kg] or saline, period of abstinence, challenge with morphine [5 mg/kg] or saline injection, brains fresh frozen
for neurochemistry experiments), with corresponding day since start of locomotor sensitization testing, and number of days for each treatment (i.e.
duration).
doi:10.1371/journal.pone.0052812.g002
Figure 3. Timeline and paradigm for operant self-administration experiment: offspring from cohort 3. Treatments are shown (oral
sucrose training, morphine self-administration at 0.1 mg/kg/infusion dose, then at 0.3 mg/kg/infusion dose, period of abstinence, cue-induced drug-
seeking), with corresponding schedule of reinforcement (FR1 and FR2, fixed ratio of 1 and 2, respectively; PR9-4 and PR3-4, progressive ratio 9-4 and
3–4, respectively [see Table 1]; no schedule of reinforcement represented by ‘–’), and corresponding number of days for each treatment schedule (i.e.
duration).
doi:10.1371/journal.pone.0052812.g003
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Cohort 1
Naltrexone and 6, b-naltrexol levels during
pregnancy. All 16 dams received a naltrexone implant, were
mated, and sampled at either gestation day 13, 15 18 or at birth,
following euthanasia (n = 4 per time-point). Offspring blood was
collected at gestation day 18 and at birth, and was pooled into one
sample per litter. At gestation days 13 and 15, amniotic fluid was
collected and also pooled into a single sample for each litter
(n = 4 per time-point). Naltrexone and 6,b-naltrexol levels in all
samples were measured as above. The sampling time-points for
maternal rats and offspring from cohorts 1, 2 and 3 are
summarised in Figure 1B.
Cohort 2
Naltrexone and 6, b-naltrexol levels before conception, at
birth and at weaning. Cohort 2 females were randomly
allocated to receive either a naltrexone or placebo implant, were
impregnated and gave birth (n = 12/treatment group). Blood was
obtained from all maternal rats 1 day prior to mating and at birth.
Offspring were either euthanised, sampled for blood and
examined at birth (from 6 maternal rats per group), or were
raised to 4 weeks, weaned, and raised until 10 weeks (using the
remaining 6 dams per group), whereupon they were transferred to
the Florey Neurosciences Institute, for evaluation of locomotor
behaviour and neurochemistry. Maternal rats fostering these
offspring had a blood sample taken at weaning. Individual blood
samples were collected from one male and one female from each
litter at weaning and at 8 weeks.
Body and brain morphometry. Duration of pregnancy,
litter size and gender were recorded. At birth and 8 weeks,
offspring body-weight was recorded and heel-toe, occipital-snout
and biparietal lengths were measured using vernier callipers. At 8
weeks, one male and female per litter were perfused transcardially
with heparinised saline (5000 IU/L), followed by 250 ml 4%
paraformaldehyde in 0.2 M phosphate buffer (pH 7.2–7.4) for
brain morphometry. Brain weight was recorded and cerebrum
length, width, height, as well as brain length (i.e. cerebrum+cer-
ebellum) were measured using vernier callipers, and brain volume
was calculated by water displacement as described previously
[28,29,30].
Behavioural sensitization. Upon arrival of offspring at the
Florey Neuroscience Institutes, animals were acclimatised for 2
weeks and no procedures were undertaken. At 12–14 weeks of age,
sensitization to locomotor responses induced by repeated mor-
phine treatment was performed as previously described [31,32].
Briefly, adult male and female offspring were placed individually
in photo-optic locomotor cells (Truscan Photobeam; Coulbourn
Instruments, Allentown, PA, USA) in a low luminosity (20 lux),
controlled environment, for 60 minutes per day for 3 consecutive
days. Vertical (rearing) and horizontal (ambulatory) movements
were measured by optic sensor beams.
Table 1. Instrumental requirement for PR9-4 and PR3-4 schedules.
Infusion Step Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Lever Response Requirement, PR9-4 1 1 1 2 2 2 3 3 4 4 5 5 6 6 7
Lever Response Requirement, PR3-4 1 2 4 6 9 12 15 20 25 32 40 50 62 77 95
Lever response requirement values indicate the number of lever presses necessary for the acquisition of each subsequent infusion (infusion step number). Progressive
increases vary between the two schedules such that for the 10th infusion, 4 lever presses will result in an infusion using the PR9-4 schedule [42], whereas 32 lever presses
are required for the 10th infusion using PR3-4 schedule [43]. Accordingly, the PR3-4 schedule is deemed more difficult as it progressively requires a greater lever
response for an infusion than the PR9-4 schedule. Rat responding for morphine was assessed in the current study using both schedules.
doi:10.1371/journal.pone.0052812.t001
Table 2. Cohort 2 offspring body and brain morphometric
measurements following maternal treatment with naltrexone
or placebo implants.
DRUG GROUP
ASSESSED PARAMETERS Placebo Naltrexone
Body Parameters at Birth n= 60 n = 70
Body Weight (g) 6.0960.08 5.4260.09***
Heel-to-toe length (mm) 9.1760.09 8.9860.10
Occipital-to-snout length (mm) 18.2160.12 18.0860.13
Biparietal length (mm) 10.5460.08 10.2960.09
Body Parameters in
Adulthood
n= 57 n = 74
Body Weight (g) 250.5162.99 256.2662.61
Heel-to-toe length (mm) 43.0660.17 43.4060.15
Occipital-to-snout length (mm) 56.9660.34 55.6660.30{
Biparietal length (mm) 24.4060.14 24.2160.12
Brain Parameters in Adult
Males
n= 29 n = 37
Brain Weight (g) 1.9260.06 1.9360.04
Brain Volume (cm3) 1.8460.05 1.8660.04
Brain Length (mm) 19.9960.13 20.0260.12
Cerebral Length (mm) 15.3560.19 15.1760.15
Cerebral Height (mm) 10.1160.19 10.2560.09
Cerebral Width (mm) 15.7460.16 15.5560.12
Brain Parameters in Adult
Females
n= 28 n = 37
Brain Weight (g) 1.7960.021 1.7660.011
Brain Volume (cm3) 1.7260.021 1.7060.011
Brain Length (mm) 19.4860.131 19.4560.061
Cerebral Length (mm) 15.0260.18 14.8760.19
Cerebral Height (mm) 9.8360.081 9.8560.121
Cerebral Width (mm) 15.5160.15 15.2560.12
Morphometric effects of maternal treatments during pregnancy and/or
weaning on offspring body parameters (body weight, foot and head lengths), at
birth and in adulthood (at 8 weeks-of-age). Morphometric effects on brain
parameters (brain [cerebral+cerebellar] weight, volume and length, and
cerebral length, height and width) are shown for adult male and female
offspring and all values represent the mean 6 SEM. Using one-way ANOVA: ***
p,0.001, significant difference for naltrexone versus placebo; { p= 0.04, trend
for difference between naltrexone versus placebo; 1 p,0.01, significant
difference for male versus female (within naltrexone or placebo group).
doi:10.1371/journal.pone.0052812.t002
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Testing proceeded as follows. Habituation to the test environ-
ment was established using 3 daily 60 min sessions within
locomotor chambers. On days 4–8, rats were placed in the
locomotor chambers 30 min after an injection of saline (1 ml/kg)
or morphine (10 mg/kg, s.c.) and activity recorded for 60 min.
From days 9–15, animals underwent a period of home-cage
abstinence (i.e. they received no injections). On day 16, rats were
challenged with saline or morphine (5 mg/kg) and returned to the
locomotor chambers (Figure 2). Treatment groups were: saline-
saline, (saline: days 4–8 and 16, SS); saline-morphine (SM);
morphine-morphine (MM).
For these experiments, we did not observe differences between
males and females. Therefore, for logistical reasons relating to
Animal Ethics approval (i.e. minimising animal numbers), only
males were used for the subsequent neurochemical and operant
self-administration experiments.
Neurochemistry. At 14 weeks, after behavioural sensitiza-
tion testing (,3 h after final treatment), male rats were terminally
anaesthetised (pentobarbitone, 80 mg/kg, i.p.) and brains re-
moved and frozen. Serial sagittal brain sections (4.2–3.4 mm
lateral to the mid-sagittal sinus, 14 mm; [33] were thaw-mounted
onto slides and stored at 280uC.
[125I]DAla2,N-Me-Phe4,Met(O)5-ol enkephalin (FK33,824) was
used to label high affinity m-opioid receptors [34,35]. Slides were
incubated in 50 mM Tris-HCl (pH 7.4; 0.1% bovine serum
albumin, 0.1 nM [125I]FK33,824, 2000 Ci/mmol) for 60 min.
Non-specific binding was determined by addition of 10 mM
naloxone to the incubation medium. Slides were washed, dried
and apposed to Biomax AR film (Kodak XAR-5) with [14C]mi-
croscales. Films were developed automatically (100 Plus Automatic
x-ray film processor: All-Pro Imaging).
Expression of PPE and PPD mRNA has previously been
described [36]. Oligonucleotides were 39-end labelled with
[a33P]d-adenosine triphosphate using terminal deoxynucleotidyl
transferase. Labelled probes (1 pg/ml, 100 ml) and applied to
adjacent sections in hybridisation buffer (50% formamide,
46saline sodium citrate, pH 7.0, 10% dextran sulfate). Controls
used a 100-fold molar excess of unlabelled oligonucleotide.
Sections were hybridised in sealed humidified chambers at 42uC
overnight, rinsed (16saline sodium citrate, 1 h, 55uC), dehydrated
in ethanol and air-dried. Dry sections were apposed to x-ray film
with [14C]microscales and then developed.
Autoradiographs showing binding of radioligand to m-opioid
receptor, and binding of oligonucleotide probes to PPE and PPD
mRNA, were captured using a Sony XC-77CE CD Video
Camera with an attached Nikon Micro-Nikkor 55 mm lens.
Sufficient contrast to background intensity allowed manual
delineation of brain regions [33]. Tissue was analysed with an
MCID M4 image analysis system under constant illumination;
Scion Image software was used to convert optical densities to
radioactivity per unit area (disintegrations per minute per
millimeter squared; DPM/mm2) by means of a calibration curve
derived from autoradiograms of the simultaneously-apposed
[14C]microscales.
Cohort 3
Naltrexone and 6, b-naltrexol levels at birth and at
weaning. Dams from cohort 3 were randomly allocated to
receive either a naltrexone or placebo implant, were mated and
gave birth. At birth, litters were reduced to 10 (5 males and 5
females) and culled neonates from each litter had blood pooled
into one sample per litter. Surviving offspring were weaned at 4
weeks, at which point maternal blood was collected, and offspring
were reared until 10 weeks of age, whereupon they were
transported to the Florey Neuroscience Institutes for assessment
for operant self-administration of morphine. Upon arrival, animals
were acclimatised for 2 weeks and no procedures undertaken.
Operant self-administration. Self-administration of intra-
venous morphine (0.1 or 0.3 mg/kg/infusion) was assessed using
operant chambers (Med Associates, USA) with two levers. Rats
were connected via a jugular cannula to an intravenous line
(polyethylene, inner diameter (ID): 0.6 mm, outer diameter (OD):
1.2 mm) connected to a 22-gauge swivel (Instech Solomon, USA)
and a syringe held in an infusion pump (PHM-100SVA; Med
Associates) with Bcoex-T22 tubing (Tygon, ID 0.6 mm, OD:
1.6 mm; Instech Soloman). A light (conditioned stimulus, CS)
came on for 20 s, contingent with an active lever press and reward
delivery. In addition, a drop of vanilla essence provided an
olfactory cue (S+) for the location of the active lever. The
chambers were housed in sound attenuated boxes and ventilated
with fans. Med-PC IV software (Med Associates) was used to
record lever presses.
The cannulae consisted of a 10 cm length of silastic tubing
(inner diameter 0.635 mm, outer diameter 1.194 mm, Dow
Corning Corporation, Midland, MI, USA) sleeved over a 22-
gauge cannula (Plastics One, Roanoke, VA, USA). All cannulae
were autoclaved. At 12 weeks, rats were anaesthetised (2–3%
isoflurane) and cannulae implanted into the jugular vein and
flushed with 0.15 ml of antibiotic (1.2 mg trimethoprim and 6 mg
sulfadoxin) and heparinised saline. Meloxicam (0.75 mg, i.p.) was
given for pain relief. The day after surgery, cannulae were flushed
with heparinised antibiotic; thereafter, cannulae were flushed
twice daily with heparinised saline. Starting on the day of
cannulation, rat daily food intake was restricted to 15 g as this is
known to facilitate self-administration of abused drugs
[37,38,39,40,41].
After 3 days of recovery in the home cage, rats underwent
operant self-administration training to respond for oral sucrose
(5%) at a fixed-ratio of 2 (FR2) schedule. Each of these training
sessions were 15 h in duration and took place once daily until lever
Table 3. The effects of maternal naltrexone, or placebo, implants on offspring.
Gender ratio:
Drug group Litters: n Male n (%) Female n (%) Litter size: mean (StdDev)Term (days): median (IQR)
Placebo 10 71 (61) 46 (39) 11.7 (2.0) 21 (21–22)
Naltrexone 10 72 (50) 72 (50) 14.4 (1.2)** 21 (21–21)
The effects of maternal implant treatments during pregnancy on total litter size (observed live and still births), sex ratio of litters and term of pregnancy. Term refers to
the length of pregnancy, measured in days. IQR = inter-quartile range. The mean and standard deviation (StdDev) are also shown (one-way ANOVA: ** p,0.01,
naltrexone versus placebo).
doi:10.1371/journal.pone.0052812.t003
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discrimination was demonstrated (after 3 days in most cases).
Subsequently, rats were connected to morphine via the jugular
cannula to the intravenous line. The injection volume was 48 ml
per infusion and duration of injection was 2.3 s. A maximum of 50
drug infusions was set, with a 20-s timeout period after an infusion.
All post-training sessions (except for cue-induced drug-seeking
session at the very end) were 2 h in length, unless 50 infusions were
obtained, and were held just before the dark phase of the
photoperiod. The active lever remained the same for both oral
sucrose training and intravenous self-administration of morphine
experiments, as did the position of the olfactory cue and
contingent light stimulus.
Rats responded for intravenous morphine (0.3 mg/kg/infusion)
at a fixed-ratio of 1 (FR1) schedule (3 weeks), with subsequent
assessment on a progressive-ratio (PR) 9–4 schedule [42] for 2
days, then PR3-4 [43] for 2 days (Table 1). The following day, the
rats were returned to FR1 as before, but using a morphine dose of
0.1 mg/kg/infusion; the order and durations for each phase of
testing were the same as for the higher morphine dose.
Subsequently, rats remained drug-free in the home cage for 6
weeks. Then, drug-seeking was assessed under extinction condi-
tions (FR1 response resulted in CS but no infusion of morphine)
for 1 h. An overview of this experimental paradigm of different
responding schedules is presented as a timeline in Figure 3.
The patency of the cannulae was evaluated periodically using
ketamine (5 mg). If loss of righting reflex was not apparent within
3 s of infusion, the rat was excluded. In addition, rats were
excluded if any cannula blockage or leakage was identified during
daily flushing. During assessment of FR1 responding for
morphine, criteria were set at a lever discrimination of $65%
and ,25% variation between the numbers of infusions over 3
days.
Statistical Analyses
Unless otherwise indicated, statistical analysis was undertaken
using SPSS for Windows and two-tailed tests. Results for free
naltrexone and 6,b-naltrexone, in blood or amniotic fluid, were
examined with Pearson Correlation coefficient between maternal
and offspring levels, stage of pregnancy and time post-implant.
Where data failed tests of normality, a Kruskal-Wallis nonpara-
metric ANOVA was employed. Results are for male and females
combined unless mentioned otherwise.
Observational and morphometric data were evaluated by one-
way ANOVA because violations of the underlying data prevented
the use of multiple analysis of variance; accordingly, to reduce the
potential for Type 1 errors [44], stringent alpha levels of p,0.0125
and p,0.008 were used for measures of body and brain
morphometry, respectively. Morphometric data are reported
separately for male and female offspring (Table 2).
Data from locomotor studies were analysed using a two-way
ANOVA, with drug treatment and exposure duration as factors,
and with post-hoc Student-Newman-Keuls analysis. To evaluate
overall differences in activity between treatment groups, a
generalised linear model for repeated measures was used.
Neurochemistry data (from examination of only male brains)
were incorporated into generalised linear mixed models for
statistical analysis using SAS; significance and interactions were
assessed between the following fixed factors: maternal drug
exposure (naltrexone and placebo); duration of morphine expo-
sure; and ligand ([125I]FK33,824)/probe ([33P]preproenkephalin,
[33P]preprodynorphin).
Operant self-administration data were obtained for male
offspring only. For time course analyses (PR and drug-seeking
cumulative responses), and analyses of the effect of implant
treatment and dose on morphine self-administration, a two-way
ANOVA was performed. Comparisons of the PR data between
the offspring groups were analysed using an unpaired t-test. Drug-
seeking data were analysed by one-way ANOVA, with Student-
Newman-Keuls post-tests. Differences were deemed significant if
p,0.05, and for pair-wise comparisons, if p,0.05 after adjust-
ments using the Dunn-Sida´k procedure.
Results
General Observations
Data from cohort 2 offspring were combined for analysis of litter
size, length of gestation and gender ratio. In cohort 2, there were
10 naltrexone-exposed litters and 10 placebo-exposed litters
which, respectively, produced 144, and 117 live pups. There were
,23% more pups per litter following maternal naltrexone
treatment compared to placebo (F(1,19) = 13.53; p,0.01; Table 3).
There was no significant effect of drug treatment on term of
pregnancy (F(1,19) = 2.70; p.0.05; Table 3), nor in gender ratio at
birth (x2(1,19) = 3.29; p.0.05; Table 3).
Naltrexone and 6, b-naltrexol Levels in Dams and
Offspring
In both dams and offspring, free 6,b-naltrexol blood-levels were
low with many below the limit of detection (.0.1 ng/mg) and a
maximum blood concentration of 0.3 ng/ml found in two
maternal samples. Nevertheless, a positive correlation existed
between naltrexone and 6,b-naltrexol maternal levels: r ,0.01,
N = 94 (data not shown).
Free naltrexone was quantified in maternal and offspring blood
samples, as well as in amniotic fluid (cohort 1). The weight-
adjusted naltrexone concentration in maternal blood was
1.1960.19 ng/ml; raw offspring naltrexone concentration in
blood or amniotic fluid was 1.2360.25 ng/ml. Further analysis
revealed that offspring levels correlated with maternal levels: r
,0.001, N = 15 (Figure 4A). Furthermore, both maternal (p,0.01)
and offspring (p,0.05) levels correlated with time post-implant
(Figure 4A).
For cohort 2, naltrexone was detected in maternal and offspring
blood at birth and at weaning (postnatal day 28). Naltrexone was
Figure 4. Free naltrexone levels in dams and offspring with naltrexone implant. Temporal profiles of free naltrexone concentration are
shown in offspring blood or amniotic fluid (A, cohort 1) or maternal blood (A and B, cohorts 1, 2 & 3.) after maternal administration with a naltrexone
implant (25 mg, s.c.). A: Temporal profiles of free naltrexone concentration in offspring blood (GD18 [purple] and Birth [blue]) or amniotic fluid (GD13
[yellow] and GD15 [green]) or maternal blood (black) after maternal administration with a naltrexone implant (25 mg, s.c.). Cohort 1 maternal and
offspring rats were sampled throughout gestation. Exponential lines of best fit are shown for maternal rats (y = 6.76e20.07x, filled line) and offspring
(y = 9.45e20.09x, dashed line). Offspring levels correlated with maternal levels (Pearson Correlation [ = 0.75] significant at 0.001 level; N = 15); and both
maternal (p,0.01; R2 = 0.62) and offspring (p,0.05; R2 = 0.55) levels correlated with the number of days post-implant. To allow appropriate
comparison with offspring, unadjusted maternal data are presented here. C: conception; GD: gestation day; B: birth. B: Maternal naltrexone-blood
levels prior to conception, at birth and at weaning from cohorts 1 (closed circles), 2 (open circles) and 3 (crosses) were associated with days post-
implant (p,0.01, N= 54; mean 6 SEM: 2.8660.62 ng/ml). A polynomial line of best fit indicated a moderate level of association (R2 = 0.68). C:
conception, B: birth, W: weaning.
doi:10.1371/journal.pone.0052812.g004
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Figure 5. Comparison of locomotor activity between offspring groups in response to a novel environment. Locomotor activity is
shown on days 1–3, after saline or morphine administration on days 4–8 (10 mg/kg, s.c.), and after a final morphine challenge on day 16 (5 mg/kg,
s.c.). A: Total activity scores in the vertical plane and B: in the horizontal plane, reveal that habituation was greater among naltrexone-exposed
offspring. C: Total horizontal locomotor activity did not differ between groups treated with saline and challenged with morphine (saline-morphine).
D: Total horizontal locomotor activity did not differ between groups treated with morphine, although sensitization was expressed in both groups
after challenge with morphine (morphine-morphine). E: Analysis of data expressing total morphine-induced locomotor activity as a function of basal
locomotor activity on day 3 revealed significantly greater activity values for naltrexone-exposed offspring, indicating an increased development of
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not detected at postnatal day 56 (adulthood). In some offspring at
weaning, naltrexone was not detected (n = 8) and these data were
excluded from the calculation of means. Unadjusted maternal
naltrexone-blood levels are reported elsewhere [45]. Here, we
report weight-adjusted maternal mean 6 SEM, which declined
from 9.7461.59 ng/ml (n = 12) at 1 day prior to conception to
1.1860.50 ng/ml (n = 5) at ,24 h of birth, 1.1860.33 ng/ml
(n = 5) at postnatal day 3 and 0.3060.15 ng/ml (n = 5) at weaning.
Offspring levels (mean 6 S.E.M) were 0.9960.27 (n = 5) at ,24 h
of birth and 0.3460.00 ng/ml (n = 3) at weaning.
At weaning, the weight-adjusted mean 6 SEM for free
naltrexone in blood from implanted females (cohort 3) was
0.9560.32 ng/ml (n = 6). Raw data for naltrexone in blood from
offspring culled at birth (pooled into one sample per litter) was
3.1761.65 ng/ml. Weight-adjusted maternal values for free
naltrexone-blood concentration with respect to the number of
days post-implant are represented for all mothers (cohorts 1, 2 and
3) in Figure 4B. Maternal blood levels sampled from all 3 cohorts
correlated with the number of days post-implant (r ,0.01, N = 54;
Figure 4B). Levels after the initial sample taken at preconception
(12 days post-implant) also correlated with days post implant (r
,0.01, N = 42; mean 6 SEM: 0.9060.12 ng/ml; Figure 4B).
Body and Brain Morphometry
Total litter size, as well as maternal weights from each group,
were used as covariates. Covariates appearing in the model of
offspring at birth were evaluated at 239.42 (mothers’ weight) and
12.66 (litter size). For offspring evaluated in adulthood, values
were 272.22 mothers’ weight and 13.67 for litter size.
After adjusting for covariates, naltrexone had a significant effect
on offspring body weight at birth (F(1,129) = 14.93; p,0.001;
Table 2). Estimated marginal means for body weight were
10.9% less in the naltrexone-group compared to that of placebo
offspring. There was also a trend for gender to impact on offspring
birth-weight (F(1,129) = 3.81; p= 0.05; Table 2), with males 3.9%
heavier than females. Both male and female pups in the naltrexone
group had lower birth-weights than placebo counterparts.
In adult offspring, there were no effects from drug treatment on
body weight (F(1,130) = 1.73; p.0.05; Table 2). There was,
however, a significant effect of gender on body weight
(F(1,130) = 14.26; p,0.001; Table 2). Naltrexone-exposed adult
offspring did not differ significantly from those exposed to placebo
with respect to occipital-to-snout length, although planned
comparison revealed a trend for naltrexone to affect head size,
with a 2.3% reduction in the estimated marginal mean of
occipital-to-snout length in naltrexone offspring when compared
to placebo (F(1,130) = 3.28; p= 0.04; Table 2).
For brain morphometry, only adult offspring were examined.
Each variable was assessed separately with drug group and gender
as fixed factors. None of the measures showed a significant main
effect of drug group or a significant group by gender interaction.
Each variable showed a significant main effect of gender at the
adjusted alpha level except for brain width (F(1,19) = 8.10; p= 0.01;
Table 2), and cerebrum length (F(1,19) = 7.70; p= 0.01; Table 2);
male offspring had larger and heavier brains (Table 2).
sensitization. Data are expressed as vertical plane entries (A) or horizontal distance moved in centimetres (B, C, D and E) and represent the mean 6
SEM (one-way ANOVA: * p,0.05, ** p,0.01, *** p,0.001; days 1–3 (A and B): placebo: n = 37, naltrexone: n = 53; days 4–16 (C): placebo: n = 12,
naltrexone: n = 19; days 4–16 (D and E): placebo: n = 20, naltrexone: n = 26).
doi:10.1371/journal.pone.0052812.g005
Figure 6. Opioid neurochemistry in brains of offspring. Evaluation of [33P]preproenkephalin (PPE) mRNA binding in the striatum (Str) by in situ
hybridisation histochemistry (ISHH), with comparison between offspring groups (placebo; naltrexone) and drug treatments received during
behavioural sensitization (saline-saline, SS; saline-morphine, SM; morphine-morphine, MM). A: Representative autoradiograms showing localisation of
[33P]PPE mRNA binding sites within midsagittal sections of whole rat brain at approximately 4.0 mm from the midline. Relative PPE mRNA expression
within Str presented in accordance with quantitative ISHH (A), which was performed as described in Materials and Methods. As indicated by the
density scale, the highest binding levels appear as black. B: Quantitative data for PPE mRNA binding in Str are expressed in disintegrations per minute
per millimetre squared (DPM/mm2) and represent the mean 6 SEM. Using generalised linear mixed modelling: * p,0.05, ** p,0.01, *** p,0.001,
naltrexone versus placebo by SS versus SM versus MM, naltrexone: n = 14; placebo: n = 17; n<5/column.
doi:10.1371/journal.pone.0052812.g006
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Locomotor Activity and Behavioural Sensitization
We did not observe differences between males and females;
accordingly, we combined them into a single data set. After initial
placement in locomotor chambers, naltrexone-exposed offspring
(males and females combined) exhibited fewer vertical plane
entries (rearing) compared to placebo-exposed offspring
(F(1,88) = 5.70; p,0.05; 32.6%; Figure 5A) and continued to
display significantly less rearing while habituating over days 2
(F(1,88) = 6.00; p,0.05; 52.3%; Figure 5A) and 3 (F(1,88) = 12.90;
p,0.001; 49.1%; Figure 5A), translating to an overall reduction of
basal activity in the vertical plane (F(1,88) = 20.45; p,0.001;
42.6%). Horizontal plane activity (ambulation) did not differ on
day 1 (F(1,88) = 1.80; p.0.05; Figure 5B), although in naltrexone-
exposed offspring, total horizontal activity was significantly
attenuated compared to placebo offspring by day 3 for males
and females combined (F(1,88) = 6.00; p,0.05; 25.3%; Figure 5B).
Given the difference in horizontal activity between treatment
groups following habituation by day 3, subsequent data for
morphine treatments were calculated as a function of basal
activity. While there was no difference between groups on the first
day of morphine treatment, from day 4 to 5 (i.e. morphine
injection day 1 to 2) there was a significantly greater increase in
ambulation of naltrexone-exposed offspring which was 11.5 fold
greater than placebo-exposed offspring (726.86248.6 cm com-
pared to 37.06204.6 cm; F(1,44) = 4.19; p,0.05; Figure 5D). From
day 5 until the completion of testing (day 16), naltrexone-exposed
offspring continued to exhibit significantly greater development of
sensitization as a function of basal activity (Figure 5E). This was
further validated using a generalised linear model for repeated
measures which confirmed 42.7% greater development of
sensitization during the induction phase and greater overall
ambulation of naltrexone-exposed offspring, in males
(F(1,20) = 5.68; p,0.05), females (F(1,22) = 9.12; p,0.01), and males
and females combined (F(1,44) = 14.98; p,0.001; Figure 5E). There
was no effect of saline injection on locomotor activity with respect
to time and, likewise, no difference between groups in response to
morphine challenge (day 16) following saline pre-treatment (saline-
morphine; F(1,29) = 0.29, p.0.05; Figure 5C).
Opioid Neurochemistry in Offspring Brains
Analysis of brains from male offspring (cohort 2), revealed a
two-way interaction between maternal treatment group (i.e.
naltrexone or placebo), treatment received during behavioural
testing (i.e. saline-saline, saline-morphine, morphine-morphine)
and PPE mRNA expression. Namely, reduced expression was
associated with placebo offspring given morphine, either as saline-
morphine (20.0%; p= 0.018) or morphine-morphine (21.4%;
p= 0.005) compared to expression in morphine-naı¨ve counterparts
(saline-saline) (Figure 6A and B). However, no reduction in
expression was found in naltrexone-exposed offspring, although
striatal PPE mRNA expression was greater in those given
morphine (saline-morphine: 29.6%; p= 0.002 or morphine-mor-
phine: 31.3%; p,0.001) compared to placebo-exposed counter-
parts (Figure 6A and B). This effect on PPE mRNA expression was
not found in other brain regions examined (Table 4). No
significant differences were found with respect to expression of
PPD mRNA or m-opioid receptor expression (Table 4).
Propensity to Self-administer Morphine
Fixed-Ratio responding. Both naltrexone- and placebo-
exposed offspring reliably self-administered morphine (Figure 7).
Analysis of mean total data for FR1 responding revealed
significant discrimination between the two levers at 0.1 mg/kg/
infusion (F(3,20) = 35.94, p,0.001; Figure 7A). Student-Neuman-
Keuls post hoc comparisons revealed significant preference for the
active lever over the inactive lever in placebo- (F(1,10) = 5.97,
Table 4. Mean 6 SEM values (DPM/mm2) for in situ hybridisation histochemistry and autoradiography binding.
MATERNAL TREATMENT
GROUP PLACEBO NALTREXONE
Offspring Treatment Group Saline-Saline Saline-Morphine Morphine-Morphine Saline-Saline Saline-Morphine Morphine-Morphine
PPE mRNA
Striatum 9.3060.48 7.4460.54* 7.3160.48** 8.7960.48 9.6460.48{ 9.5960.401
Dentate Gyrus 9.3260.52 10.1260.58 10.5060.51 10.3660.52 9.5760.51 9.2960.43
Cortex 8.1760.42 8.1060.42 8.6960.70 7.2160.54 7.6060.46 8.1560.54
PPD mRNA
Striatum 0.6560.36 0.6960.40 0.5760.34 0.5660.43 0.6460.35 0.5560.31
Dentate Gyrus 2.5460.45 2.6160.51 2.3760.44 2.0360.49 2.0060.45 2.2660.38
m-Opioid Receptor
Striatum 2.7360.48 2.6260.55 2.5960.48 4.0260.48 3.2360.48 3.7560.36
Cortex 1.9260.06 2.2260.09 2.2060.14 2.1960.11 1.9060.09 2.2160.11
Thalamic Nucleus 2.0760.07 1.9160.13 1.6860.11 2.2660.13 1.8660.12 1.9560.15
Medial Geniculate Nucleus 4.5960.19 4.6460.35 4.6260.25 5.3360.31 4.6060.25 4.2460.26
Dorsal Hippocampus 2.5060.10 2.7460.11 2.4360.15 2.6160.14 2.2860.11 2.2060.07
Ventral Hippocampus 7.0060.31 7.0260.27 6.4460.60 7.2360.32 6.5860.38 5.9760.39
Quantitative data for [33P]preproenkephalin (PPE) mRNA, [33P]preprodynorphin (PPD) mRNA and [125I]FK33,824 (m-opioid receptor) binding in various regions of male rat
brains (striatum, dentate gyrus, cortex, thalamic nucleus, medial geniculate nucleus dorsal hippocampus) with comparison between maternal treatment groups
(placebo; naltrexone). Using generalised linear mixed modelling, significant differences were found in PPE mRNA binding in striatum: * p,0.05, ** p,0.01 for significant
differences with respect to saline-saline treated offspring from maternal rats implanted with placebo; { p,0.01 for significant difference with respect to saline-morphine
treated offspring from maternal rats implanted with placebo; 1 p,0.001 for significant difference with respect to morphine-morphine treated offspring from maternal
rats implanted with placebo; naltrexone: n = 14; placebo: n = 17; n < 5/column.
doi:10.1371/journal.pone.0052812.t004
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p= 0.035) and naltrexone-exposed rats (F(1,10) = 13.54, p= 0.004).
Significant discrimination was also evident at 0.3 mg/kg/infusion
(F(3,38) = 18.68, p,0.001; Figure 7B) with post hoc comparisons
revealing significant preference for the active lever over the
inactive lever in both placebo- (F(1,22) = 17.58, p,0.001) and
naltrexone-exposed rats (F(1,16) = 33.68, p,0.001).
Analysis of the number of morphine infusions received over 7
days revealed an overall significantly augmented response by
naltrexone-exposed offspring at 0.3 mg/kg/infusion over this
period (F(1,15) = 6.17, p= 0.025). This difference between groups
was not observed over a similar period at 0.1 mg/kg/infusion
(F(1,7) = 0.90, p.0.05). At 0.3 mg/kg/infusion, there was a
significant escalation in morphine self-administration by naltrex-
one-offspring, with greater consumption on day 7 compared to
day 1 (t(14.63) = 2.57, p= 0.022; Figure 7D). However, as there was
a lack of escalation in self-administration at 0.1 mg/kg/infusion
(t(16.16) = 0.75, p.0.05; Figure 7C), FR1 testing at the lower dose
was undertaken for 6 days. The number of timeout responses did
not differ between placebo- and naltrexone-exposed offspring at
either 0.1 (F(1,10) = 0.47, p.0.05) or 0.3 mg/kg/infusion
(F(1,19) = 3.50, p.0.05) (data not shown).
Progressive-ratio responding. No difference was seen
between placebo- and naltrexone-exposed offspring for 0.1 mg/
kg/infusion assessed on the PR3-4 schedule with respect to active
lever presses (t(10) = 0.83, p.0.05), breakpoint (t(10) = 0.85, p.0.05),
drug infusions (t(10) = 0.83, p.0.05), or overall cumulative response
(F(1,10) = 0.38, p.0.05) (data not shown). However, at 0.3 mg/kg/
infusion, naltrexone-exposed rats displayed a higher breakpoint
compared to placebo offspring on a PR3-4 schedule. Unpaired t-
tests revealed a significant difference between offspring groups
with respect to the final ratio obtained (breakpoint) (t(12) = 2.91,
p= 0.013; Figure 8B), total number of lever presses for the session
Figure 7. Comparison of naltrexone- and placebo-exposed offspring to fixed ratio morphine self-administration. Morphine self-
administration under a fixed-ratio of 1 lever press and acquisition of a stable response. Data are expressed as the number of active versus inactive
lever responses per 2 h session over 6 days for dose of 0.1 mg/kg/infusion (A), and over 7 days for 0.3 mg/kg/infusion (B), and represent the mean6
SEM (two-way ANOVA, * p,0.05, ** p,0.01, *** p,0.001, compared to the active lever, 0.1 mg/kg/infusion: placebo: n = 6, naltrexone n= 6; 0.3 mg/
kg/infusion: placebo: n = 12, naltrexone: n = 9). Data are expressed as number of infusions and amount of morphine (mg/kg) obtained each day over 6
days for dose of 0.1 mg/kg/infusion (C) and over 7 days for 0.3 mg/kg/infusion (D) represent the mean 6 SEM (no difference between groups using
two-way ANOVA).
doi:10.1371/journal.pone.0052812.g007
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(t(12) = 2.82, p= 0.015; Figure 8A) and number of infusions
(t(12) = 3.01, p= 0.011; Figure 8C). Furthermore, when assessing
the proportion of rats that reached a ‘true breakpoint’ (when no
reinforcer is earned for a 60 min period), none of the 7 naltrexone-
exposed rats reached a ‘true breakpoint’ in the 2-h session,
whereas 4 of the 7 placebo-exposed rats (57%) did. This is
apparent as the clear plateau in the responding of placebo- but not
for the naltrexone-exposed offspring when examining cumulative
responses (Figure 8D).
Analysis of cumulative responding revealed a significant effect of
offspring group (F(1,13) = 9.24; p= 0.012; Figure 8D) and time
(F(11,66) = 44.06; p,0.001), and a significant interaction between
the two factors (F(1.36,16.28) = 6.89, p= 0.012). Dunn-Sida´k post test
comparisons revealed no difference between placebo- and
naltrexone-exposed offspring in the first 10 min time bin
(p.0.05; Figure 8D) but cumulative responses were significantly
greater among naltrexone-exposed offspring, compared to those
exposed to placebo, in all remaining time bins (20–120 min:
t= 7.97, 12.42, 17.61, 22.14, 27.19, 31.58, 32.11, 33.94, 36.64,
39.53 and 39.50, respectively, p,0.05 for all except from 60 to
70 min time bins, p,0.01; Figure 8D).
For the PR9-4 schedule (data not shown) at 0.3 mg/kg/
infusion, groups differed with respect to breakpoint (t(11) = 2.29,
p= 0.043) and infusions (t(11) = 2.30, p= 0.042). Cumulative
responses were significantly greater in naltrexone-, compared to
placebo-exposed rats, in the 30, 40 and 90 min time bins (t= 2.37,
2.20 and 2.23, respectively, with p#0.05).
Cue-induced drug-seeking. Both groups exhibited robust
cue-conditioned drug-seeking behaviour after a period of absti-
nence (Figure 9). Nonetheless, overall cumulative responses for the
active lever were greater among naltrexone-exposed offspring
(F(1.69,23.68) = 4.77, p= 0.023; Figure 9A). Dunn-Sida´k post hoc test
comparisons revealed no difference between placebo- and
naltrexone-exposed offspring in the first 10 min time bin
(t(14) = 1.41, p.0.05; Figure 9A) but cumulative responses were
significantly greater among naltrexone-exposed offspring, com-
pared to placebo, in all remaining time bins (20–60 min: t= 2.68,
2.94, 2.73, 2.73 and 2.70, respectively, p,0.05; Figure 9A). A
Figure 8. Comparison of naltrexone- and placebo-exposed offspring to progressive ratio morphine self-administration. Morphine
self-administration under a progressive ratio (PR) schedule of 3–4 (see Table 1 for response requirement) at a dose of 0.3 mg/kg/infusion. Data from
the PR3–4 session are expressed as total active lever presses (A), breakpoint, defined as the final ratio completed within the 2 h session (B), and
number of drug infusions (C) and represent the mean 6 SEM (unpaired t-test, * p,0.05, naltrexone versus placebo (n = 7). D: Cumulative response
record for the PR3-4 session divided into 10 minute time bins. Data are expressed as number of active lever presses and represent mean6 SEM (two-
way ANOVA, * p,0.05, ** p,0.01, naltrexone versus placebo (n = 7) for each time bin).
doi:10.1371/journal.pone.0052812.g008
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plateau in responding was evident for both placebo- (40 to 60 min)
and naltrexone-exposed offspring (50 to 60 min) (Figure 9A).
Active lever presses were significantly higher on test day (1-h
session) compared to baseline responding (2-h session), despite the
absence of drug infusions during the session. This significant cue-
conditioned drug-seeking was revealed by two-way ANOVA
(F(7,66) = 16.62, p,0.001; Figure 9B), and Student-Newman–Keuls
post hoc analyses for placebo- (p= 0.018; 130%) and naltrexone-
exposed offspring (p,0.001; 163%), confirming enhanced re-
sponding in naltrexone-exposed offspring on the active lever on
test day compared to the FR1 schedule. Moreover, compared to
placebo, there was augmented active lever responding by
naltrexone-exposed offspring on the cue-induced drug-seeking test
day versus baseline day (F(1,14) = 11.48, p= 0.005; 73%; Figure 9B).
Furthermore, during the cue-induced drug-seeking session,
naltrexone-exposed offspring exhibited significantly greater active
lever responding relative to inactive lever presses (p,0.001; 124%;
Figure 9B); conversely, among placebo rats, responding was
comparable between active and inactive levers. There was no
difference in latency to first active lever press between naltrexone-
and placebo-exposed offspring (F(1,14) = 0.046, p.0.05).
Discussion
Maternal Naltrexone Exposure Induces Behavioural
Changes in Adult Offspring
Previous animal studies have shown that prenatal exposure to
cocaine, cannabis and morphine leads to an increased propensity
to self-administer drugs in adulthood [46,47,48] although no effect
was observed following prenatal morphine exposure in another
study [49]. Nonetheless, the current study is the first to suggest that
maternal exposure to sustained-release naltrexone during gestation
and lactation confers increased opioid abuse risk in adulthood.
The enhanced morphine self-administration in naltrexone-ex-
posed offspring suggests that morphine may have an increased
‘reward value’. Furthermore, increases in breakpoint on a PR
schedule suggest increased motivation to obtain the drug [50].
Although both groups showed robust morphine-seeking after 6
weeks of abstinence, naltrexone-exposed offspring exhibited
significantly more responses, supporting enhanced relapse-like
drug-seeking in naltrexone-treated offspring.
Increased drug-seeking behaviour reflects neuroadaptations that
occur with repeated drug exposure [51,52]. Our findings suggest
that developmental opioid receptor antagonism may cause
pathophysiological changes that contribute to compulsive drug-
seeking behaviour. One possible explanation is that in utero
naltrexone exposure may negatively impact upon circuits neces-
sary for extinction learning which would also explain an
apparently increased motivation to obtain morphine under PR.
Interestingly, the endogenous opioid system has been implicated in
goal-directed learning as opioid receptor antagonism facilitates the
transition from goal-oriented to habitual responding [53]. The
present data, therefore, suggest that developmental opioid receptor
antagonism may impact upon the pathways implicated in habit-
forming. Clearly, a definitive answer for the mechanism behind
increased self-administration of opiates and relapse propensity in
adult rats exposed to naltrexone in utero requires further
investigation. One possibility is that striatal enkephalin signalling
is altered following naltrexone exposure, as implicated by the
neurochemical data. Another possibility is that, rather than
naltrexone exposure underlying an increase in reward, the
observed increase in operant responding for morphine and cue-
Figure 9. Comparison of naltrexone- and placebo-exposed offspring to cue-induced drug-seeking. Cue-induced drug seeking (cues
present but no drug infusions;1 h) after an abstinence period of 6 weeks with comparison between offspring groups (placebo, naltrexone). A:
Cumulative response record for cue-induce drug-seeking divided into 10 minute time bins. Data are expressed as number of active lever presses and
represent mean 6 SEM (two-way ANOVA, * p,0.05, naltrexone (n = 9) versus placebo (n = 7) for each time bin). B: Total active and inactive lever
presses during the drug-seeking session (represented by white bars, placebo: n = 9, naltrexone: n = 7) as compared to lever presses during 7 days of
stable responding under a fixed-ratio 1 (represented by black bars, placebo: n = 12, naltrexone: n = 9). Data expressed as number of lever presses and
represent mean 6 SEM (one-way ANOVA: * p,0.05, ** p,0.01, *** p,0.001, naltrexone versus placebo).
doi:10.1371/journal.pone.0052812.g009
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induced drug seeking may be a pharmacodynamic effect from
naltrexone-induced changes in opioid G-protein receptor coupling
or other signalling pathways [54,55]. Regardless of the mecha-
nism, we suggest that our data argue for long-term follow-up of
human cases of foetal naltrexone exposure. For example, the
present data provide a strong argument for interrogation of the
epigenetic effects of in utero naltrexone exposure that may underpin
some of the behavioural differences noted in our current study.
Significant differences between naltrexone- and placebo-ex-
posed offspring occurred at the 0.3 mg/kg but not the 0.1 mg/kg
morphine dose, consistent with an inverted U-shaped dose-response
[56,57], highlighting the importance of using different drug doses.
Moreover, the collective data suggest an increased reinforcing
strength of morphine in naltrexone-exposed rats that may relate to
the relative resistance of striatal enkephalin expression to
morphine-induced down-regulation compared to placebo rats.
Naltrexone-exposed offspring exhibited lower vertical activity
(rearing) compared to placebos, when first introduced to a novel
environment. During subsequent re-exposure to the same envi-
ronment, less rearing (i.e. habituation) occurred in both groups
and remained lower in the naltrexone-exposed group, consistent
with other studies [12,58]. In addition, although similar levels of
overall ambulation (horizontal activity) are consistent with other
studies [17,58,59], we show apparently increased habituation in
this plane. Reduced locomotor activity in a novel environment,
particularly rearing, could indicate reduced exploratory drive [58]
and/or altered motivational systems [60,61].
Moderate morphine doses in rats produce a biphasic locomotor
response [62,63], which was observed acutely in both naltrexone-
and placebo-exposed offspring. Tolerance, the attenuation of a
response over a period of chronic drug treatment [64], and
sensitization, the increase in a response that arises from repeated
drug treatment [62,65], are different neuroadaptive processes that
can occur concomitantly. Repeated morphine treatment produces
a decrease in its sedative effects (tolerance) and an increase in its
stimulatory effects on locomotion (sensitization) [63,66]. Changes
in vertical and horizontal activity can be used respectively to assess
tolerance and sensitization [67]. Drug-induced locomotor sensiti-
zation is a robust and well-established indicator of plasticity that
may relate to aspects of addiction [19,20]. Although the expression
of sensitization did not differ between groups, naltrexone-exposed
offspring showed a greater transition from an initial morphine-
induced depressant response to a stimulant response after repeated
morphine treatment, suggesting enhanced development of sensi-
tization.
Interestingly, this was mirrored by resistance of striatal
enkephalin mRNA expression to down-regulation following
morphine treatment compared to placebos. Enkephalin appears
to mediate morphine-induced tolerance and sensitization
[21,22,23] via networks known to regulate motor behaviour.
Treatment of placebo-exposed offspring with morphine was
associated with decreased striatal PPE mRNA expression relative
to saline-treated placebo rats. However, this effect did not occur in
naltrexone-exposed offspring, indicating that morphine-induced
regulation of enkephalin was a normal process [68,69] not evident
following naltrexone-exposure during development. Importantly,
this occurred in adult rats that had been free of naltrexone since
weaning; indicating that developmental exposure to naltrexone
can result in enduring behavioural changes and neurochemical
alterations to central opioid systems.
Although an effect was observed for PPE mRNA, no such
changes were seen for PPD mRNA or m-opioid receptor
expression. Other studies have shown changes to opioid receptors
following naltrexone exposure [70,71]. For example, in adult mice
implanted with 15 mg naltrexone pellets, up-regulation of m- and
d-opioid receptors was observed after 7 days of naltrexone pre-
treatment [72]. Given that up-regulation of m- and d-opioid
receptors correlate with potency changes of morphine [71,73]
further studies in our model would be interesting to examine
whether changes to k- and/or d-opioid receptors play a role in the
behavioural effects we observed.
Gross Morphological Changes Following Maternal
Naltrexone Exposure are Minimal
Persistent behavioural effects occurred in the absence of
substantial morphological changes in adult offspring but were
preceded by decreased birth-weights. Because litter size impacts on
growth and nutritional intake [74,75], we incorporated the
naltrexone-associated increase in litter size as a covariate and
showed that decreases in neonatal body weight occurred
independently of litter size. Consistent with our findings, offspring
body weight in mice is reduced following low-dose maternal
naltrexone [76] and is associated with intermittent postnatal
opioid receptor antagonism [77,78]. Reduced birth-weight and
head-size following low maternal and foetal naltrexone exposure
(,2 ng/ml) is also consistent with the general inhibitory effects of
low-dose opioid receptor antagonism [13,17,77,78,79,80,81,82].
The trend toward reduced adult offspring head-size, not evident at
birth, highlights the need for follow-up in naltrexone-exposed
human newborns who appear to be developmentally unaffected
[6,8,9,83].
A Pregnant Rat Model for Sustained-release Naltrexone
The sustained-release naltrexone preparation comprised the
same formulation used in humans and yielded comparable release-
(,0.4 mg/kg/day) and blood-levels (,2–10 ng/ml) [7,10]. Fol-
lowing intraperitoneal injection in rat, naltrexone undergoes
placental transfer [84] but does not remain in pre-weaning
offspring blood for more than 2 days after the last injection [85].
Using our customised implant, we have shown transfer of
naltrexone to the amniotic fluid, blood and lactate. Humans and
rats are also similar with respect to naltrexone’s affinity for opioid
receptors [86,87], plasma protein binding [88] and rate of
elimination [89,90], with a half-life range of 2–14 hours in
humans [91,92], and 4.6–11.4 hours in rats [93,94].
In relative terms, brain development in rats and humans occurs
to a common timetable defined by the time between conception
and eye opening (‘‘caecal period’’ rat: 36 days; human: 182 days).
When expressed as a percentage of the caecal period, neurode-
velopmental milestones start and finish at approximately the same
value [95,96,97]. Based on caecal period calculations, blood-
naltrexone levels were sustained above 1 ng/ml, comparable to
levels in humans, for a clinically comparable amount of time (.30
days in rat < 5.5 months in humans). Moreover, the decline in
naltrexone levels in maternal rat plasma was similar to the profiles
in non-pregnant humans [10,98] and a single case study of a
pregnant woman [7].
Future animal studies investigating the developmental effects of
sustained-release naltrexone, particularly on addiction-related
behaviours, would provide greater insight in the clinical context
if maternal rats were opioid-dependent prior to treatment with
naltrexone. Nonetheless, the current study still has much to offer as
a clinically-relevant model in that there are a number of potential
therapeutic uses for naltrexone in the non-opioid dependent
patient, including in the management of alcoholism [3,4,99],
compulsive gambling [100,101,102,103], multiple sclerosis
[104,105,106] and obesity [107,108,109].
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The current study highlights the vulnerability of the developing
brain to drug exposure. Indeed, factors such as ‘‘imprinting’’ may
be critical at the time of birth. For example, in humans, obstetric
administration of opiates, barbiturates or nitrous oxide (.1 hour)
during labour and within 10 hours of birth increased the relative
risk of offspring subsequently becoming addicted to opiates in
adulthood [110,111,112]. Our model examined continuous
naltrexone exposure during pregnancy and lactation but, in future
studies, may be of value to determine whether much shorter
critical period/s of exposure also produce effects in adult offspring.
Conclusion
The current study demonstrates that chronic, low-dose maternal
naltrexone delivered via a sustained-release implant impacts both
behaviour and neurochemistry in adult offspring, but without
obvious morphological effects. Our data are consistent with
perturbations that are reported to result from naltrexone exposure
during development with significant implications for alterations in
morphine-induced neuroplasticity, and increased risk of opioid-
abuse later in life. Our findings highlight the need for greater
information on the safety of using naltrexone during human
pregnancy.
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